Instil Bio Inc. (TIL)

NASDAQ: TIL · Real-Time Price · USD

12.71

-0.14 (-1.09%)

At close: May 01, 2025, 11:08 AM

-1.09% (1D)

Bid	9.18
Market Cap	83.4M
Revenue (ttm)	n/a
Net Income (ttm)	-74.14M
EPS (ttm)	-11.39
PE Ratio (ttm)	-1.12
Forward PE	-0.88
Analyst	Buy

Ask	12.83
Volume	9,207
Avg. Volume (20D)	112,157
Open	12.84
Previous Close	12.85
Day's Range	12.53 - 12.82
52-Week Range	9.62 - 92.00
Beta	1.76

About TIL

Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 to recognize f...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Mar 19, 2021

Employees 14

Stock Exchange NASDAQ

Ticker Symbol TIL

Website https://instilbio.com

Full Company Profile

Analyst Forecast

According to 4 analyst ratings, the average rating for TIL stock is "Buy." The 12-month stock price forecast is $110, which is an increase of 765.12% from the latest price.

Stock Forecasts